US Broker Ratings

Tilray Brands, Inc. (TLRY) Stock Analysis: Exploring a Potential 28% Upside in the Cannabis Sector

Tilray Brands, Inc. (NASDAQ: TLRY), a key player in the global cannabis industry, presents a unique investment opportunity with its expansive portfolio and international reach. With..

Ardelyx, Inc. (ARDX) Stock Analysis: Unpacking a 70% Potential Upside in the Biotech Sector

Ardelyx, Inc. (NASDAQ: ARDX), a biotech company listed on the NASDAQ exchange, is making waves in the healthcare sector with its innovative approach to addressing unmet..

uniQure N.V. (QURE) Stock Analysis: Uncovering a 143.91% Potential Upside in the Biotech Sector

uniQure N.V. (NASDAQ: QURE) is a shining beacon in the biotechnology industry, captivating investors with its innovative approach to treating rare and devastating diseases. Based in..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Strong Buy Ratings Amid Potential 7% Upside

Maze Therapeutics, Inc. (MAZE), a burgeoning player in the biotechnology sector, is captivating investor attention with its robust pipeline of precision medicines targeting renal and cardiovascular..

Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotech Frontier with Potential Upside

Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company that has carved a niche in the healthcare sector by focusing on innovative protein degradation therapies. Headquartered..

Personalis, Inc. (PSNL) Stock Analysis: Navigating Growth Challenges with Strategic Collaborations

Personalis, Inc. (NASDAQ: PSNL), a key player in the healthcare sector’s diagnostics and research industry, is at a critical juncture. With a market capitalization just shy..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Promising 315% Potential Upside in Biotechnology

Investors with a keen eye on the biotechnology sector may find Anavex Life Sciences Corp. (NASDAQ: AVXL) an intriguing prospect. Positioned in the healthcare industry, Anavex..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 46% Potential Upside for Investors

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a dynamic player in the biotechnology sector, is capturing investor attention with its compelling 46.42% potential upside, as suggested by..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with 90% Upside Potential

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is making waves in the biotechnology sector with a compelling growth narrative. As a commercial-stage company, Day One is dedicated..

Standard BioTools Inc. (LAB) Stock Analysis: Navigating the -3.73% Potential Downside in a Competitive Medical Device Landscape

Investors with an eye on the healthcare sector, particularly those focused on medical devices, might find Standard BioTools Inc. (NASDAQ: LAB) an intriguing subject of analysis...

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 112.50% Potential Upside in the Healthcare Sector

Organogenesis Holdings Inc. (NASDAQ: ORGO), a notable player in the regenerative medicine landscape, is capturing investor attention with a striking potential upside of 112.50%. As the..

COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a 135.88% Potential Upside in Mental Health Innovation

COMPASS Pathways Plc (NASDAQ: CMPS) is currently capturing the attention of investors with its promising advancements in mental health treatments and an intriguing potential upside of..

Verastem, Inc. (VSTM) Stock Analysis: Exploring a 141% Potential Upside in the Promising Biotech Sector

Verastem, Inc. (NASDAQ: VSTM), a U.S.-based biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to cancer treatment. As a development-stage company,..

Gyre Therapeutics, Inc. (GYRE) Investor Outlook: A Potential 123% Upside in the Biotech Space

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a pioneering biopharmaceutical company, is making waves in the healthcare sector with its innovative approach to tackling organ fibrosis through small-molecule..

MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a Potential 42.85% Upside in Biotech Innovation

MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies, is garnering significant attention from investors due to its promising pipeline and potential..

Neuropace, Inc. (NPCE) Stock Analysis: A 12.97% Potential Upside with Strong Buy Ratings

Neuropace, Inc. (NASDAQ: NPCE), a pioneering company in the medical device sector, is capturing investor attention with its innovative solutions in the treatment of drug-resistant focal..

Kura Oncology, Inc. (KURA) Rating Update: 258% Potential Upside Highlights Growth Potential in Biotech Sector

Kura Oncology, Inc. (NASDAQ: KURA), a prominent player in the biotech sector, continues to capture investor attention with its promising pipeline of cancer therapies. Headquartered in..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside

AbCellera Biologics Inc. (NASDAQ: ABCL), a Canadian biotechnology firm, presents an exciting opportunity for investors in the healthcare sector with a remarkable potential upside of 111.93%...

EyePoint, Inc. (EYPT) Stock Analysis: Unpacking the 120.9% Potential Upside

EyePoint, Inc. (NASDAQ: EYPT), a dynamic player in the biotechnology sector, has captured investor attention with a promising 120.9% potential upside, according to analyst ratings. Specializing..

Inventiva S.A. (IVA) Stock Analysis: Exploring a 108.61% Potential Upside with Strong Buy Ratings

Inventiva S.A. (IVA), a French biotechnology company listed on the American Depositary Receipt (ADR) market, is capturing investor attention with its promising pipeline and compelling analyst..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds